Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Prurigo nodularis (PN) is a chronic skin dermatosis with hyperkeratotic and intensely pruritic nodules. Managing PN‐associated itch is difficult because its aetiology is still unknown. This study aimed to investigate the correlation between itch intensity in PN and the expression of a pruritogenic cytokine interleukin (IL)‐31, its receptor complex components IL‐31 receptor α (IL‐31RA) and oncostatin M receptor β (OSMRβ), and oncostatin M (OSM), which is a ligand of OSMR β, through immunofluorescence staining examination. Itch intensity in PN was closely correlated with the number of dermal IL‐31(+) cells (Spearman's r = 0.551, p < 0.05), dermal IL‐31RA(+) cells (r = 0.475, p < 0.05) and dermal OSM(+) cells (r = 0.505, p < 0.05). In addition, the number of dermal OSMRβ (+) cells was increased in PN (t test, p < 0.05), despite not being correlated with itch intensity (Spearman's r = 0.375, p > 0.05). Major cellular sources of dermal IL‐31 were T cells (27.0% of total IL‐31–expressing cells) and macrophages (35.0%), while those of OSM were mainly T cells (49.8%) and mast cells (26.8%). IL‐31RA–expressing dermal cells were mostly mast cells (49.3%) and macrophages (36.6%), and OSMRβ was mainly expressed by macrophages (51.8%) in the dermis. These findings indicate that IL‐31 (mainly from macrophages and T cells) and OSM (principally from T cells and mast cells) stimulate dermal cells expressing IL‐31RA and OSMRβ (e.g. macrophages), which may further promote itch and inflammation in PN. This complex dermal milieu of cell/cytokine/receptor network can be a therapeutic target for PN‐associated itch.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
Ständer, S., Yosipovitch, G., Legat, F. J., Lacour, J.-P., Paul, C., Narbutt, J., Bieber, T., Misery, L., Wollenberg, A., Reich, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1908316 · Cited by 281
Self-citationOncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology
Hermanns, H. M. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.07.006 · Cited by 263
Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis
Furue, M., Yamamura, K., Kido‐Nakahara, M., Nakahara, T., & Fukui, Y. (2018) · Allergy · doi:10.1111/all.13239 · Cited by 240
Interleukin‐31 and interleukin‐31 receptor: New therapeutic targets for atopic dermatitis
Nakashima, C., Otsuka, A., & Kabashima, K. (2018) · Experimental Dermatology · doi:10.1111/exd.13533 · Cited by 154
Dai, X., Okazaki, H., Hanakawa, Y., Murakami, M., Tohyama, M., Shirakata, Y., & Sayama, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067666 · Cited by 88
Oncostatin M and its role in fibrosis
Stawski, L., & Trojanowska, M. (2019) · Connective Tissue Research · doi:10.1080/03008207.2018.1500558 · Cited by 86
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
Sofen, H., Bissonnette, R., Yosipovitch, G., Silverberg, J. I., Tyring, S., Loo, W. J., Zook, M., Lee, M., Zou, L., Jiang, G.-L., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101826 · Cited by 108
Self-citationHashimoto, T., Yokozeki, H., Karasuyama, H., & Satoh, T. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.11.009 · Cited by 96
Self-citation
Metadata
- Authors
- Hashimoto, T., Nattkemper, L. A., Kim, H. S., Kursewicz, C. D., Fowler, E., Shah, S. M., Nanda, S., Fayne, R. A., Paolini, J. F., Romanelli, P., & Yosipovitch, G.
- Venue
- Experimental Dermatology
- Publisher
- Wiley
- Published
- 2021-02
- Volume
- 30
- Issue
- 6
- Pages
- 804-810
- ISSN
- 0906-6705 (ISSN-L)
- 1600-0625
- OpenAlex
- W3119986538
- Cited by
- 116
- References
- 7
- FWCI
- 13.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta. https://app.cochat.ai/papers/10.1111/exd.14279
- The paper
- Hashimoto, T., Nattkemper, L. A., Kim, H. S., Kursewicz, C. D., Fowler, E., Shah, S. M., Nanda, S., Fayne, R. A., Paolini, J. F., Romanelli, P., & Yosipovitch, G. (2021). Itch intensity in prurigo nodularis is closely related to dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha and oncostatin M receptor beta. Experimental Dermatology. https://doi.org/10.1111/exd.14279
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.